Alembic Pharma Posts 21% Profit Growth on Strong US Generics Demand

Alembic Pharmaceuticals has reported strong financial results for the second quarter of fiscal year 2026, with consolidated net profit rising approximately 21% year-on-year to ₹185 crore and revenue increasing 16% to ₹1,910 crore. The growth was largely driven by robust performance in its US generics business, which saw a 21% revenue jump supported by three new product launches and six ANDA approvals, bringing the total to 226. The company also completed the acquisition of Utility Therapeutics, marking its entry into the US branded drugs market, further enhancing its global footprint. EBITDA rose 32% to ₹315.3 crore, and the EBITDA margin expanded to 16.5%, reflecting improved operational efficiency and profitability. Alembic's management highlighted continued momentum across core businesses, with significant investments in research and development to build a strong pipeline for future growth. Following the announcement, the company’s shares surged over 6%, reflecting investor optimism about its steady operational performance and international market traction.